Frederic Revah | Chief Executive Officer

Frederic Revah, Chief Executive Officer, Genethon

As the Chief Executive Officer of Genethon, Frédéric Revah has more than twenty years’ experience in the pharmaceutical and biotech industries as well as in academic research. Immediately prior to joining Genethon in January 2010, he had been Chief Executive Officer at Sepal Pharma (oncology), before which he was CEREP’s Vice-President of Drug Discovery and Scientific Director from 1999-2007, as well as being Chief Executive Officer of its oncology arm. He was also head of the CNS Gene Therapy Department and the Neurochemistry Department at Rhône-Poulenc Rorer (now Sanofi-Aventis) from 1992 to 1998.
Frédéric Revah started his career as an associate staff researcher at the Institut Pasteur (from 1990 to 1992). He obtained his doctorate at the Institut Pasteur / Université de Paris V in 1991, and graduated from the Ecole Polytechnique engineering school in 1985.


Day 2 Orphan 15th Nov @ 09:55

Introducing a new industrial player emerging from a patient organisation, for the industrialisation of cell & gene therapies to be commercialised at a fair price

  • Materializing research outcomes into products
  • The role of a patient group, AFM-Telethon from innovation to production
  • Ability to provide production to pharma and biotech
  • Using new models to give a fair opportunity to all stakeholders

back to speakers